|
1
|
Kamangar F1, Qiao YL, Schiller JT, Dawsey
SM, Fears T, Sun XD, Abnet CC, Zhao P, Taylor PR and Mark SD: Human
papillomavirus serology and the risk of esophageal and gastric
cancers: results from a cohort in a high-risk region in China. Int
J Cancer. 119:579–584. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics for Hispanics/Latinos, 2012. CA Cancer J Clin.
62:283–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gaur P, Kim MP and Dunkin BJ: Esophageal
cancer: Recent advances in screening, targeted therapy, and
management. J Carcinog. 13:112014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ahvazi B, Kim HC, Kee SH, Nemes Z and
Steinert PM: Three-dimensional structure of the human
transglutaminase 3 enzyme: Binding of calcium ions changes
structure for activation. EMBO J. 21:2055–2067. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hitomi K, Horio Y, Ikura K, Yamanishi K
and Maki M: Analysis of epidermal-type transglutaminase (TGase 3)
expression in mouse tissues and cell lines. Int J Biochem Cell
Biol. 33:491–498. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hitomi K: Transglutaminases in skin
epidermis. Eur J Dermatol. 15:313–319. 2005.PubMed/NCBI
|
|
8
|
Hitomi K, Presland RB, Nakayama T,
Fleckman P, Dale BA and Maki M: Analysis of epidermal-type
transglutaminase (transglutaminase 3) in human stratified epithelia
and cultured keratinocytes using monoclonal antibodies. J Dermatol
Sci. 32:95–103. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kalinin AE, Kajava AV and Steinert PM:
Epithelial barrier function: Assembly and structural features of
the cornified cell envelope. BioEssays. 24:789–800. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eckert RL, Sturniolo MT, Ann-Marie B,
Monica R and Rorke EA: Transglutaminase function in epidermis. JJ
Invest Dermatol. 124:481–492. 2005. View Article : Google Scholar
|
|
11
|
Guang HE, Zhao Z, Weineng FU, Sun X,
Zhenming XU and Sun K: Study on the loss of heterozygosity and
expression of transglutaminase 3 gene in laryngeal carcinoma.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 19:120–123. 2002.In
Chinese.
|
|
12
|
Uemura N, Nakanishi YH, Saito S, Nagino M,
Hirohashi S and Kondo T: Transglutaminase 3 as a prognostic
biomarker in esophageal cancer revealed by proteomics. Int J
Cancer. 124:2106–1255. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Negishi A, Masuda M, Ono M, Honda K,
Shitashige M, Satow R, Sakuma T, Kuwabara H, Nakanishi Y, Kanai Y,
et al: Quantitative proteomics using formalin-fixed
paraffin-embedded tissues of oral squamous cell carcinoma. Cancer
Sci. 100:1605–1611. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Méndez E, Fan W, Choi P, Agoff SN, Whipple
M, Farwell DG, Futran ND, Weymuller EA Jr, Zhao LP and Chen Cl:
Tumor-specific genetic expression profile of metastatic oral
squamous cell carcinoma. Head Neck. 29:803–814. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Viatour P, Merville MP, Bours V and
Chariot A: Phosphorylation of NF-kappaB and IkappaB proteins:
Implications in cancer and inflammation. Trends Biochem Sci.
30:43–52. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li B, Li YY, Tsao SW and Cheung AL:
Targeting NF-kappaB signaling pathway suppresses tumor growth,
angiogenesis, and metastasis of human esophageal cancer. Mol Cancer
Ther. 8:2635–2644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bassères DS and Baldwin AS: Nuclear
factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic
initiation and progression. Oncogene. 25:6817–6830. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang L, Liu X, Jin H, Guo X, Xia L, Chen
Z, Bai M, Liu J, Shang X, Wu K, et al: miR-206 inhibits gastric
cancer proliferation in part by repressing cyclinD2. Cancer Lett.
332:94–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cotter TG: Apoptosis and cancer: The
genesis of a research field. Nat Rev Cancer. 9:501–507. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Darius W, Ilja M, Margitta E, Christian K
and Barbara K: Tumor necrosis factor alpha triggers proliferation
of adult neural stem cells via IKK/NF-kappaB signaling. BMC
Neurosci. 7:1–18. 2006. View Article : Google Scholar
|
|
22
|
Palumbo R, Galvez BG, Pusterla T, De
Marchis F, Cossu G, Marcu KB and Bianchi ME: Cells migrating to
sites of tissue damage in response to the danger signal HMGB1
require NF-kappaB activation. J Cell Biol. 179:33–40. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu Y and Zhou BP:
TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and
invasion. Br J Cancer. 102:639–644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wong GS, Lee JS, Park YY, Klein-Szanto AJ,
Waldron TJ, Cukierman E, Herlyn M, Gimotty P, Nakagawa H and Rustgi
AK: Periostin cooperates with mutant p53 to mediate invasion
through the induction of STAT1 signaling in the esophageal tumor
microenvironment. Oncogenesis. 2:e592013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kaz AM, Luo Y, Dzieciatkowski S, Chak A,
Willis JE, Upton MP, Leidner RS and Grady WM: Aberrantly methylated
PKP1 in the progression of Barrett's esophagus to esophageal
adenocarcinoma. Genes Chromosomes Cancer. 51:384–393. 2012.
View Article : Google Scholar
|
|
26
|
Shigaki H, Baba Y, Watanabe M, Murata A,
Ishimoto T, Iwatsuki M, Iwagami S, Nosho K and Baba H: PIK3CA
mutation is associated with a favorable prognosis among patients
with curatively resected esophageal squamous cell carcinoma. Clin
Cancer Res. 19:2451–2459. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shah AK, Cao KA, Choi E, Chen D, Gautier
B, Nancarrow D, Whiteman DC, Saunders NA, Barbour AP, Joshi V, et
al: Serum glycoprotein biomarker discovery and qualification
pipeline reveals novel diagnostic biomarker candidates for
esophageal adenocarcinoma. Mol Cell Proteomics. 14:3023–3039. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Isozaki Y, Hoshino I, Nohata N, Kinoshita
T, Akutsu Y, Hanari N, Mori M, Yoneyama Y, Akanuma N, Takeshita N,
et al: Identification of novel molecular targets regulated by tumor
suppressive miR-375 induced by histone acetylation in esophageal
squamous cell carcinoma. Int J Oncol. 41:985–994. 2012.PubMed/NCBI
|
|
29
|
Uemura N, Nakanishi Y, Kato H, Saito S,
Nagino M, Hirohashi S and Kondo T: Transglutaminase 3 as a
prognostic biomarker in esophageal cancer revealed by proteomics.
Int J Cancer. 124:2106–2115. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu X, Cao W, Wang X, Zhang J, Lv Z, Qin X,
Wu Y and Chen W: TGM3, a candidate tumor suppressor gene,
contributes to human head and neck cancer. Mol Cancer. 12:1512013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu J, Zhou Y, Wan J and Liu Z: Expression
of TGM3 protein and its significance in laryngeal carcinoma. Lin
Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 26:101–103. 2012.In
Chinese. PubMed/NCBI
|
|
32
|
Ye H, Yu T, Temam S, Ziober BL, Wang J,
Schwartz JL, Mao L, Wong DT and Zhou X: Transcriptomic dissection
of tongue squamous cell carcinoma. BMC Genomics. 9:692008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kondoh N, Ishikawa T, Ohkura S, Arai M,
Hada A, Yamazaki Y, et al: Gene expression signatures that classify
the mode of invasion of primary oral squamous cell carcinomas. Mol
Carcinog. 47:744–756. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lorand L and Graham RM: Transglutaminases:
Crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell
Biol. 4:140–156. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Griffin M, Casadio R and Bergamini CM:
Transglutaminases: Nature's biological glues. Biochem J.
368:377–396. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Candi E, Schmidt R and Melino G: The
cornified envelope: A model of cell death in the skin. Nat Rev Mol
Cell Biol. 6:328–340. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu W, Yu ZC, Cao WF, Ding F and Liu ZH:
Functional studies of a novel oncogene TGM3 in human esophageal
squamous cell carcinoma. World J Gastroenterol. 12:3929–3932. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Karin M and Greten FR: NF-kappaB: Linking
inflammation and immunity to cancer development and progression.
Nat Rev Immunol. 5:749–759. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sourbier C, Danilin S, Lindner V, Steger
J, Rothhut S, Meyer N, Jacqmin D, Helwig JJ, Lang H and Massfelder
T: Targeting the nuclear factor-kappaB rescue pathway has promising
future in human renal cell carcinoma therapy. Cancer Res.
67:11668–11676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Robe PA, Bentires-Alj M, Bonif M, Rogister
B, Deprez M, Haddada H, Khac MT, Jolois O, Erkmen K, Merville MP,
et al: In vitro and in vivo activity of the nuclear factor-kappaB
inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res.
10:5595–5603. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Abdel-Latif MMM, O'Riordan J, Windle HJ,
Carton E, Ravi N, Kelleher D and Reynolds JV: NF-kappaB activation
in esophageal adenocarcinoma: Relationship to Barrett's metaplasia,
survival, and response to neoadjuvant chemoradiotherapy. Ann Surg.
239:491–500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Abdel Latif MM, O'Riordan JN, Kelleher D
and Reynolds JV: Activated nuclear factor-kappaB and cytokine
profiles in the esophagus parallel tumor regression following
neoadjuvant chemoradiotherapy. Dis Esophagus. 18:246–252. 2005.
View Article : Google Scholar
|
|
43
|
Konturek PC, Nikiforuk A, Kania J, Raithel
M, Hahn EG and Mühldorfer S: Activation of NFkappaB represents the
central event in the neoplastic progression associated with
Barrett's esophagus: A possible link to the inflammation and
overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci.
49:1075–1083. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Izzo JG, Correa AM, Wu TT, Malhotra U,
Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, et
al: Pretherapy nuclear factor-kappaB status, chemoradiation
resistance, and metastatic progression in esophageal carcinoma. Mol
Cancer Ther. 5:2844–2850. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Izzo JG, Malhotra U, Wu TT, Ensor J,
Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, et al:
Association of activated transcription factor nuclear factor kappab
with chemoradiation resistance and poor outcome in esophageal
carcinoma. J Clin Oncol. 24:748–754. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Izzo JG, Malhotra U, Wu TT, Luthra R,
Correa AM, Swisher SG, Hofstetter W, Chao KS, Hung MC and Ajani JA:
Clinical biology of esophageal adenocarcinoma after surgery is
influenced by nuclear factor-kappaB expression. Cancer Epidemiol
Biomarkers Prev. 16:1200–1205. 2007. View Article : Google Scholar : PubMed/NCBI
|
